Overview
Corinne Dror-Maurice practices practicing medicine in Haifa, Israel.
Her clinical expertise encompasses Prostate Cancer and Non-Small Cell Lung Cancer (NSCLC).
She is actively involved in clinical research, co-authoring 11 peer reviewed articles and participating in 1 clinical trial.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
1 Clinical Trials
Frequently Asked Questions about Corinne Dror-Maurice
Is Corinne Dror-Maurice a top-rated expert for Prostate Cancer?
MediFind is an objective health platform that identifies experts based on real-world data. Corinne Dror-Maurice is classified as an Experienced expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Corinne Dror-Maurice participate in research or clinical trials?
Yes. Corinne Dror-Maurice has published 11 articles and abstracts on conditions like Prostate Cancer. You can view a list of Corinne Dror-Maurice's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Non-Small Cell Lung Cancer (NSCLC)Ms. Dror-Maurice isExperienced. Learn about Non-Small Cell Lung Cancer (NSCLC).
- Prostate CancerMs. Dror-Maurice isExperienced. Learn about Prostate Cancer.